Compare · DCGO vs OPCH
DCGO vs OPCH
Side-by-side comparison of DocGo Inc. (DCGO) and Option Care Health Inc. (OPCH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCGO and OPCH operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- OPCH is the larger of the two at $3.15B, about 58.6x DCGO ($53.8M).
- Over the past year, DCGO is down 66.1% and OPCH is down 36.6% - OPCH leads by 29.5 points.
- OPCH has been more active in the news (13 items in the past 4 weeks vs 2 for DCGO).
- OPCH has more recent analyst coverage (15 ratings vs 10 for DCGO).
- Company
- DocGo Inc.
- Option Care Health Inc.
- Price
- $0.54-2.72%
- $20.07-2.00%
- Market cap
- $53.8M
- $3.15B
- 1M return
- -13.45%
- -3.28%
- 1Y return
- -66.09%
- -36.63%
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 2
- 13
- Recent ratings
- 10
- 15
DocGo Inc.
DocGo, Inc. provides mobile health services and integrated medical mobility solutions in 26 states in the United States and the United Kingdom. The company's AI-powered transportation and concierge medical services enable its clinical professionals to facilitate patient-centered care, helping improve patient outcomes while reducing the total cost of care for its customers. It also provides medical transport services. As of October 1, 2021, the company had 3,500 medical providers. It serves facilities, hospital networks, and health insurance providers. The company was founded in 2015 and is headquartered in New York, New York.
Option Care Health Inc.
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies. It also offers infusion therapies for bleeding disorders; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications. In addition, the company offers therapies that women need to survive and thrive through high-risk pregnancies; treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; and nursing services. The company is headquartered in Bannockburn, Illinois.
Latest DCGO
- DocGo Launches Mobile Phlebotomy Services in South Florida
- DocGo Announces Upcoming Participation at the Goldman Sachs 47th Annual Global Healthcare Conference
- Chief Executive Officer Bienstock Lee covered exercise/tax liability with 15,644 shares, decreasing direct ownership by 0.56% to 2,801,826 units (SEC Form 4)
- SEC Form 10-Q filed by DocGo Inc.
- DocGo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- DocGo Announces First Quarter 2026 Results
- DocGo Announces Upcoming Participation at the 21st Annual Needham Technology, Media, & Consumer Conference
- DocGo to Announce First Quarter 2026 Results on Monday, May 11, 2026
- SEC Form DEFA14A filed by DocGo Inc.
- SEC Form DEF 14A filed by DocGo Inc.
Latest OPCH
- Goldman initiated coverage on Option Care Health with a new price target
- Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
- Option Care Health Awarded TIME's World's Most Impactful Companies 2026 Ranking
- Director Bierbower Elizabeth D was granted 8,997 shares, increasing direct ownership by 38% to 32,871 units (SEC Form 4)
- Director Deckmann Natasha was granted 9,841 shares, increasing direct ownership by 44% to 32,002 units (SEC Form 4)
- Director Kraemer Harry M Jansen Jr was granted 21,076 shares, increasing direct ownership by 5% to 471,076 units (SEC Form 4)
- Director Pate R Carter was granted 8,997 shares, increasing direct ownership by 77% to 20,620 units (SEC Form 4)
- Director Sullivan Timothy P was granted 13,833 shares, increasing direct ownership by 19% to 87,216 units (SEC Form 4)
- Director Bodem Barbara W. was granted 8,997 shares, increasing direct ownership by 74% to 21,087 units (SEC Form 4)
- Director Wright Norman L. was granted 8,997 shares, increasing direct ownership by 58% to 24,498 units (SEC Form 4)